Dermatology & Aesthetics

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research . The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

Founded in Barcelona in 1943, Almirall has evolved from a general pharmaceutical manufacturer into one of Europe's leading speciality pharma companies with an exclusive focus on dermatology . Listed on the Barcelona Stock Exchange (ticker: ALM), the company directs its entire research, development and commercial infrastructure towards skin disease, giving it a depth of therapeutic expertise rarely matched by larger, more diversified pharmaceutical groups. Dermatology Portfolio and Pipeline Almirall's marketed portfolio spans several significant skin conditions. Ilumetri (tildrakizumab) targets moderate-to-severe plaque psoriasis via selective IL-23 inhibition. Klisyri (tirbanibulin) addresses actinic keratosis, a precancerous skin condition with high prevalence in sun-exposed populations. Seysara (sarecycline) provides a narrow-spectrum antibiotic option for acne, while Skilarence (dimethyl fumarate) is indicated for adults with moderate-to-severe plaque psoriasis. The company continues to build its pipeline through internal R&D and strategic licensing agreements, with atopic dermatitis representing a key area of expansion. Almirall operates commercially across Europe and North America, working directly with dermatologists, healthcare systems and specialist pharmacy channels. Its medical affairs and market access teams support reimbursement and formulary positioning in individual national markets. The company's singular therapeutic focus has positioned it as a recognised partner for academics, patient advocacy groups and clinical networks operating within the dermatology community. Further information is available at almirall.com.